Innoviva, Inc. (INVA)

NASDAQ: INVA · IEX Real-Time Price · USD
15.26
+0.02 (0.13%)
Mar 4, 2024, 4:00 PM EST - Market closed
0.13%
Market Cap 976.68M
Revenue (ttm) 310.46M
Net Income (ttm) 179.72M
Shares Out 63.23M
EPS (ttm) 2.20
PE Ratio 6.94
Forward PE 25.36
Dividend n/a
Ex-Dividend Date n/a
Volume 1,015,160
Open 15.19
Previous Close 15.24
Day's Range 14.97 - 15.45
52-Week Range 10.64 - 16.86
Beta 0.57
Analysts Hold
Price Target 15.17 (-0.59%)
Earnings Date Feb 29, 2024

About INVA

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. In... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 5, 2004
Employees 112
Stock Exchange NASDAQ
Ticker Symbol INVA
Full Company Profile

Financial Performance

In 2023, Innoviva's revenue was $310.46 million, a decrease of -6.30% compared to the previous year's $331.34 million. Earnings were $179.72 million, a decrease of -15.99%.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for INVA stock is "Hold." The 12-month stock price forecast is $15.17, which is a decrease of -0.59% from the latest price.

Price Target
$15.17
(-0.59% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

4 days ago - Business Wire

10 stocks you can bet on being inflation-proof

New research shows that “quality” stocks — companies with high operating profitability but which are out of favor on Wall Street — are the type of stocks most likely to do well if inflation heats up. ...

Other symbols: AMCWCXWHCCOTTRPCARRDN
5 days ago - Market Watch

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reporte...

4 months ago - Business Wire

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

GENEVA & WALTHAM, Mass.--(BUSINESS WIRE)--The Global Antibiotic Research & Development Partnership (GARDP), in collaboration with Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasda...

4 months ago - Business Wire

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today plans to present an oral abstract and four poster sessions from their p...

5 months ago - Business Wire

Innoviva to Participate in the Cantor Global Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Rai...

5 months ago - Business Wire

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that XACDURO® (sulbactam for injection; durlobactam for injection) is n...

6 months ago - Business Wire

Innoviva Appoints Stephen Basso as Chief Financial Officer

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announ...

6 months ago - Business Wire

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reporte...

7 months ago - Business Wire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK , July 13, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim...

8 months ago - PRNewsWire

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DE...

8 months ago - PRNewsWire

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Rai...

9 months ago - Business Wire

FDA approves Innoviva's bacterial pneumonia treatment

The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.

10 months ago - Market Watch

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that the U.S. Food and Drug Administration (FDA) approved XACDURO® (sul...

10 months ago - Business Wire

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA) focused on delivering innovative therapies in critical care and infectious disease, toda...

10 months ago - Business Wire

Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reporte...

10 months ago - Business Wire

Innoviva Announces Retirement of Board Chairman

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the “Board”) today ann...

11 months ago - Business Wire

Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S.

11 months ago - Business Wire

Innoviva Stock Trading Halted Today

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Nasdaq has ...

11 months ago - Business Wire

Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. ...

1 year ago - Business Wire

Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reporte...

1 year ago - Business Wire

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

MARINA DEL REY, Calif. , Jan. 10, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophag...

Other symbols: ARMP
1 year ago - PRNewsWire

Four Undervalued Healthcare Stocks for 2023

These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.

Other symbols: EXELPFEREGN
1 year ago - MarketBeat

Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S...

1 year ago - Business Wire